Neutrophil-to-Lymphocyte Ratio as a Predictor of Disease Severity and Mortality in Coronavirus Disease 2019: Prospective Study From Central India

Bharatsing D. Rathod 1, Dnyanesh Amle 2, Rajashree S. Khot 3, Kiran Kumar Prathipati 3, Prashant P. Joshi 3

1. General Medicine, All India Institute of Medical Sciences, Nagpur, IND 2. Biochemistry, All India Institute of Medical Sciences, Nagpur, IND 3. Otorhinolaryngology, All India Institute of Medical Sciences, Nagpur, IND

Abstract

Background: Clinical presentation of coronavirus disease 2019 (COVID-19) varies from an asymptomatic state to severe disease characterized by acute respiratory distress syndrome, respiratory failure, thrombosis, and multi-organ dysfunction syndrome. The neutrophil-to-lymphocyte ratio (NLR) has been reviewed as one of the laboratory factors that have been proposed to predict the severity of disease and mortality in COVID-19 pandemic.

Aim and objectives: To evaluate the association between NLR and the disease severity and mortality in COVID-19.

Materials and methods: After approval from Institutional Ethics Committee, this prospective cohort study was carried out in a tertiary-care teaching medical institute of Central India. COVID-19 patients of the age group 18 years and above admitted during the study period were included. Cases were categorized into four groups as asymptomatic (Group A), mild (Group B), moderate (Group C), and severe (Group D) based on clinical symptoms, respiratory rate, oxygen saturation, and chest imaging. NLR was calculated by doing a complete blood count at the time of hospitalization by the Mindray BC-6000 auto hematology analyzer. The outcome of the disease was classified as recovery and death during hospitalization. Receiver operating characteristic (ROC) curve analysis was used to assess the ability of NLR at admission to predict severe COVID-19 or mortality. Ordinal regression analysis was used to assess the impact of NLR on disease severity and mortality.

Results: Mean NLR was significantly higher in the severe COVID-19 group as compared to the mild/moderate group and in deceased as compared to discharged cases. ROC curve analysis revealed NLR to be an excellent predictor of disease severity as well as a prognostic parameter for risk of death. NLR was found to be a significant independent positive predictor for contracting the severe disease (Odd’s ratio 1.396, 95% CI=1.112-1.753, p=0.004) and mortality (Odd’s ratio 1.276, 95% CI=1.085-1.499, p=0.003).

Conclusion: High NLR was significantly associated with the disease severity and mortality in COVID-19.

Introduction

The recent coronavirus disease 2019 (COVID-19) pandemic has resulted in significant morbidity and mortality worldwide. It has affected more than 452,201,500 individuals and caused more than 6,029,850 deaths all over the world to date [1]. This number is expected to rise further due to the possibility of subsequent waves. Presentation of COVID-19 varies widely among individuals, remaining as a mild illness affecting the upper respiratory tract only in the majority of cases. But in a few cases, it can progress to involve the lower respiratory tract, worsening to acute respiratory distress syndrome (ARDS), respiratory failure, multiple organ dysfunction syndrome (MODS), and subsequent mortality. Many risk factors have been associated with the severity of disease and mortality in COVID-19 [2].

Due to the overburdening of the healthcare system in a pandemic situation, it is important to do triaging of the COVID-19 cases, so that individuals having risk factors for progression to the severe disease can be given proper medical care on a priority basis. Thus, it is important to find predictors for severity and mortality in COVID-19. The host immune system plays a very important role in the pathogenesis of COVID-19, and Aggressive inflammatory response to severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) can lead to a "cytokine storm" correlating directly with lung injury, multi-organ failure, and unfavorable
prognosis of severe COVID-19 [3,4]. Emerging evidence suggested that peripheral blood neutrophil-to-lymphocyte ratio (NLR) can be used as a marker of systemic inflammation [5,6]. NLR has shown good predictive values on progression and clinical outcomes in various diseases such as chronic obstructive pulmonary disease (COPD), cardiovascular disease, and pancreatitis [7-9]. Recently, many studies have reported the role of NLR in differentiating mild/moderate cases from severe COVID-19 cases. Several studies have proposed that NLR can be a reliable predictor of COVID-19 progression and found that elevated NLR was associated with high mortality in COVID-19 [10-14].

NLR is cost-effective, readily available, and easy to calculate laboratory marker. There are very few studies documenting the role of NLR in COVID-19 from this region. With this background, the current study has been carried out to find out the association of NLR with the severity of disease and treatment outcome (recovery or death) among laboratory-confirmed cases of COVID-19 admitted in a tertiary-care teaching medical institute of Nagpur city, Central India.

Materials And Methods
This prospective cohort study was carried out in a tertiary-care teaching medical institute of Nagpur city. The study was approved by the Institutional Ethics Committee (All India Institute of Medical Sciences, Nagpur, approval no. IEC/Pharmac/2020/140 dated: July 2, 2020). Nagpur was one of India’s highest disease burden cities, especially during the second wave of COVID-19. All consecutive cases of COVID-19 hospitalized for one year (from July 2020 to June 2021) were included in this study. Patients less than 18 years old, critically ill patients (unable to talk/give interview), pregnant women, not knowing Hindi/English or Marathi language, and those refusing to give consent were excluded. The participants were recruited within 24 hours of their admission. The data were collected by the investigators using a pre-designed structured proforma. Cases were interviewed about socio-demographic information, details of their current illness, past illnesses including comorbidities, and any substance use patterns. After obtaining medical history, clinical examinations were done and recorded in the schedule. All the interview and clinical examinations were carried out maintaining COVID-19-related government protocol, i.e., social distancing and aseptic procedure. Diagnosis of COVID-19 was made by positive reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-COV-2 from nasopharyngeal or oropharyngeal sampling. The reports of those participants who got COVID tested from any government-registered laboratory outside the hospital were also considered valid. Blood samples were collected immediately after their recruitment using institutional standard operating procedures (SOPs), for testing complete blood count, serum ferritin, and C-reactive protein. All diagnostic tests were carried out using the validated technique in accredited laboratories maintaining SOPs. The patients were categorized into four groups as asymptomatic (Group A), mild (Group B), moderate (Group C), and severe (Group D) based on clinical symptoms, respiratory rate, oxygen saturation, and chest imaging (see definition part). NLR was calculated by dividing neutrophil percentage by lymphocytes. The outcomes of the disease were classified as recovery and death during hospitalization (Figure 1).
FIGURE 1: Recruitment and assessment flowchart for the participants

NLR: neutrophil-to-lymphocyte ratio; COVID-19: coronavirus disease 2019

Operational definitions

The severity of COVID-19 disease was categorized according to the guidelines of the World Health Organization and as per the interim treatment guidelines issued by the Ministry of Health and Family Welfare, Government of India, based on the patients’ respiratory status and oxygen saturation, the cases were divided into four groups: asymptomatic, mild, moderate, and severe [15].

Asymptomatic: No symptoms. Vital parameters: stable, SpO₂ ≥ 94%, no clinical and/or radiological evidence of lower respiratory tract infection/pneumonia.

Mild: Mild symptoms of upper respiratory tract infection, vital parameters: stable, SpO₂ ≥ 94%, no clinical and/or radiological evidence of lower respiratory tract infection/pneumonia.

Moderate: Any one of these 1) respiratory rate ≥ 24/minute, 2) SpO₂ ≤ 93%, along with symptoms like shortness of breath.

Severe: Any one of these 1) respiratory rate > 30/minute, 2) SpO₂ < 95%, along with symptoms like shortness of breath/evidence of ARDS, respiratory failure requiring assisted ventilation, MODS.

Patients were monitored daily throughout their hospitalization course and outcomes were recorded. The patients who did not take the complete course of treatment and left against medical advice were excluded from the study. Main outcome variables include the severity of the illness and treatment outcome (death/discharge).

Ethical issues

Institutional Ethics Committee approval was obtained before initiating the study (IEC/Pharmac/2020/140 dated 2nd July 2020). After approaching the study participants at their convenient time, they were explained the purpose of the study. They were included in the study after obtaining informed written consent. Anonymity and confidentiality were maintained throughout the process. Separate permission was obtained for blood collection and testing. It was ensured that they could opt-out at any time during study and their routine services will not be hampered if they deny participating. The data were stored in the password-
protected file and data security was ensured.

Statistical analysis
The data were represented as frequency (percentage), mean (standard deviation), median (interquartile range). Linearity of all quantitative data was assessed using Kolmogorov Smirnov analysis and tests of statistical significance (analysis of variance (ANOVA) followed by post hoc Tukey’s Honest Significant Difference (HSD) or Kruskal-Wallis test followed by post hoc Dunnet’s test) were used as per the data type. Receiver operating characteristic (ROC) curve analysis was used to assess the ability of NLR at admission to predict severe COVID-19 or mortality. Ordinal regression analysis was used to assess the impact of individual parameters on disease severity and mortality. SPSS software, version 19.0 (Statistical Package for the Social Sciences Inc, Chicago, IL, USA) was used to carry out statistical analysis. A significance level of <0.05 was considered statistically significant.

Results
The total study population of 748 subjects was divided into four subgroups depending on the severity of their illness. A maximum number of subjects were found to be having a mild illness (Group B, n=566, 48.93%) while 236 subjects (Group A, 31.55%) were asymptomatic, 75 subjects had moderate symptoms (Group C, 10.02%), and 44 subjects had severe symptoms (Group D, 5.88%). The severity of symptoms was found to be significantly increasing with age (p<0.001), however, four study groups were matched for gender (p=0.074). Symptoms such as fever (p<0.001), dry cough (p<0.001), shortness of breath (p<0.001), and sore throat (p<0.001) were found to be significantly higher in frequency in Groups C and D compared to rest of the groups.

History of hypertension was noted to be significantly higher in Group C and Group D compared to Group A and B (p<0.001). NLR was found to be significantly different between study groups (p<0.001). Further, on post hoc analysis, it was found to be significantly higher in subjects with moderate (Group C, median 3, IQR 3–5) and severe COVID-19 (Group D, median 8, IQR 5–12.5) compared to both asymptomatic (Group A, median 2, IQR 1–2) and mild COVID-19 (Group B, median 2, IQR 1–2). Also, NLR was significantly higher in Group D compared to Group C.

C-reactive protein, lactate dehydrogenase, ferritin, and D-dimer levels were compared between study groups and were found to be significantly different. On post hoc analysis, all three parameters were found to be significantly higher in Group B, C, and D compared to Group A except for ferritin. Also, these levels were significantly higher in Groups C and D compared to Group A. A similar trend of significantly higher levels of these parameters in Group D compared to Group C was observed (Table 1).
A strong uphill correlation of NLR was noted with D-dimer levels ($r=0.658$), however, the moderate uphill correlation was noted with disease severity ($r=0.53$) and other parameters of disease severity viz. CRP, LDH, and ferritin. All the correlations were found to be statistically significant ($p<0.0001$) (Table 2).

**Table 1: Relationship between demographic and medical parameters with the severity of COVID-19**

One-way ANOVA used, aChi-square test used, aKruskal-Wallis test used

IHD: ischemic heart disease; CRP: C-reactive protein; LDH: lactate dehydrogenase; NLR: neutrophil-lymphocyte ratio; COVID-19: coronavirus disease 2019
TABLE 2: Correlation analysis of NRL with disease severity and associated parameters

| NLR | Correlation Coefficient | CRP (mg/L) | LDH (IU/L) | Ferritin (ng/ml) | D-dimer (mcg/ml) |
|-----|-------------------------|------------|------------|------------------|-----------------|
|     | 0.530^                  | 0.529^     | 0.586^     | 0.551^           | 0.638^          |
| Sig. (two-tailed) (p-value) | <0.0001     | <0.0001    | <0.0001    | <0.0001          | <0.0001         |

^statistically significant correlation

CRP: C-reactive protein; LDH: lactate dehydrogenase; NLR: neutrophil-lymphocyte ratio

ROC curve analysis revealed NLR to be an excellent predictor of disease severity (sensitivity 93.3% and specificity 87.8%) at a cut-off of >3.89 as well as a prognostic parameter for risk of death (sensitivity 96.3% and specificity 88.3%) at cut-off of >4.14 (Table 3, Figures 2A-2B).

TABLE 3: Prognostic significance of NLR at admission to predict disease severity and death in COVID-19

| Test Result Variable(s) | NLR cut-off | Area | Sensitivity (%) | Specificity (%) | P-value |
|-------------------------|-------------|------|-----------------|-----------------|---------|
| Disease severity        | >3.89       | 0.933| 93.2            | 87.8            | <0.0001 |
| Death                   | >4.14       | 0.959| 96.3            | 88.3            | <0.0001 |

Ordinal logistic regression analysis was performed to predict the risk of contracting severe COVID-19 and mortality depending on various markers at admission. NLR was found to be strongest and only significant independent positive predictor for contracting severe disease (Odd’s ratio 1.396, 95% CI=1.112-1.753, p=0.004) and mortality (Odd’s ratio 1.276, 95% CI=1.085-1.499, p=0.003) (Table 4).
| Parameter  | Odd’s ratio (Low) | Odd’s ratio (high) | Wald’s X² (Low) | Wald’s X² (high) | P-value | Odd’s ratio (Low) | Odd’s ratio (high) | Wald’s X² (Low) | Wald’s X² (high) | P-value |
|------------|------------------|-------------------|----------------|----------------|---------|------------------|------------------|----------------|----------------|---------|
| NLR        | 1.396            | 1.112             | 1.753          | 8.280          | 0.004   | 1.276           | 1.085            | 1.499          | 8.719          | 0.003   |
| CRP        | 1.039            | 1.018             | 1.060          | 13.590         | 0.000   | 1.020           | 1.003            | 1.038          | 5.020          | 0.025   |
| LDH        | 0.998            | 0.992             | 1.004          | 0.534          | 0.465   | 1.002           | 0.997            | 1.007          | 0.629          | 0.428   |
| Ferritin   | 1.000            | 0.999             | 1.002          | 0.241          | 0.623   | 1.000           | 0.999            | 1.002          | 0.190          | 0.663   |
| D-dimer    | 1.002            | 1.001             | 1.004          | 8.691          | 0.003   | 1.002           | 1.000            | 1.003          | 7.346          | 0.007   |

**TABLE 4: Ordinal logistic regression analysis to predict the risk of contracting severe COVID-19 and mortality**

CRP: C-reactive protein; COVID-19: coronavirus disease 2019; LDH: lactate dehydrogenase; NLR: neutrophil-lymphocyte ratio

### Discussion

NLR is defined as the absolute neutrophil count (ANC)/absolute lymphocyte count (ALC) [16]. Since the beginning of the pandemic, studies have been investigating the role of NLR in COVID-19 prognostication and its utility as a biomarker of severity. NLR has been reported to prognosticate mortality, progression to severe disease, risk of intubation, risk of severe disease in intubated patients, days intubated, ICU admission, and longer intensive care unit (ICU) admission [10-14,17-20]. Two meta-analyses of n=19 and n=13 studies found significant associations between higher NLR and COVID-19 severity and mortality [21,22]. Earlier studies found links to higher NLR in chronic conditions with low-grade inflammatory nature, such as obesity, hypertension, diabetes mellitus, atherosclerotic events of the heart and brain, and various cancers [7-9,23]. NLR might maintain its predictive ability for COVID-19 severity even in patients with comorbidities. For instance, NLR significantly predicted COVID-19 severity and survival in hospitalized patients with different types of cancers [24]. These underlying diseases are risk factors for severe COVID-19. It has been suggested that each increased NLR unit resulted in an 8% higher mortality in COVID-19 patients [25].

Apart from NLR, two other studied markers from complete blood count were platelet to lymphocyte ratio (PLR) and monocyte to lymphocyte ratio (MLR). But out of these, NLR outperformed in prognosticating mortality compared with PLR and LMR [26]. NLR could predict progression to ARDS and the need for mechanical ventilation [27]. There is wide variation in the clinical severity of COVID-19 ranging from an asymptomatic state to severe disease characterized by ARDS, respiratory failure, and MODS. Around 20% of hospitalized cases develop severe disease and in-hospital case fatality due to COVID-19 has been reported as 2-3% by multiple studies [28,29].

Various factors have been proposed to affect disease severity in COVID-19. The present study aimed to assess the association between NLR and severity of disease and mortality in COVID-19. We found a significant difference in NLR levels among discharged and deceased, being significantly higher in later. NLR was significantly higher in severe diseases. There was a significant difference in age, comorbidities, inflammatory markers between discharged and deceased. Our study findings are consistent with the results of previous similar studies. Several meta-analyses have reported that patients with severe COVID-19 infection had a higher NLR than those with non-severe COVID-19 infection [10-14,21,22].

In COVID-19 patients, the absolute value of peripheral white blood cells is usually normal or low, and lymphopenia is common. However, in severe COVID-19 disease, the lymphocyte count decreases progressively, while the neutrophil count gradually increases. This may be due to excessive inflammation and immune suppression caused by the SARS-COV-2 infection [30]. Neutrophils are regarded as proinflammatory cells with a range of antimicrobial activities, which can be triggered by virus-related inflammatory factors, such as IL-6 and IL-8 [31]. On the other hand, systemic inflammation triggered by SARS-COV-2 significantly depresses cellular immunity, leading to a decrease in CD4+ T cells and CD8+ T cells. In addition, SARS-COV-2-infected T cells may also cause cytotoxic effects on T cells [32]. The higher NLR resulted from the increased neutrophil count and decreased lymphocyte count. The NLR reflects the balance between innate immunity (neutrophils) and adaptive immunity (lymphocytes). As increased NLR indicates more systemic inflammation, more inflammatory tissue damage, and raised inflammatory markers. In severe cases, the higher NLR indicated that the immune system was dysregulated more severely and could not dampen the overactive innate immune response. These inflammatory overactivation responses might aggravate the production of a cytokine storm and worsen tissue damage [33]. Cytokine storm is the main cause of death in the late stage of SARS-CoV-2 infection [34].
Studies have shown that on-admission NLR could predict COVID-19 prognosis and can be used as a risk stratification tool. This predictive ability increases for a few days after admission when NLR reaches its peak. However, NLR gradually loses its predictive ability as inflammation reduces and the patient recovers from COVID-19 [35,36]. Measurement of NLR requires a complete blood count with differentials, a routine, cheap, widely available, and simple laboratory test. At last, various COVID-19 variants are showing different outcomes of morbidity and mortality [37]. Therefore, we suggest future researchers update the findings related to systemic inflammatory markers specifically for emerging variants.

The main strength of this study was that it tried to highlight a relatively unexplored domain on the prognosis of COVID-19 patients. Further, this research captured COVID-19 patients with a wide range of disease severity and compared NLR levels in patients with different disease severity. Also, many potential predictors of mortality in COVID-19 patients were tested.

Our study has several limitations. Being a single-center study, the study has limited external validity. Further, a single measurement of NLR within 24 hours of hospitalization and a lack of a control group are other limitations. We suggest multicenter studies to clarify the role of NLR in the severity of disease and mortality in COVID-19.

Conclusions

High NLR was significantly associated with disease severity and mortality in COVID-19 patients in our study. Based on our study, NLR can be used as an early warning signal for severe COVID-19 disease, however further studies are required to validate this finding and it had a significant correlation with other inflammatory markers of COVID-19 severity like CRP, D-dimer, and serum ferritin.

Being a simple, easily available, cost-effective investigation, on-admission NLR could predict COVID-19 prognosis and can be used as a risk stratification tool. In view of various emerging COVID-19 variants with different outcomes of morbidity and mortality, future research is needed to update the findings related to systemic inflammatory markers specifically for emerging variants.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee, All India Institute of Medical Sciences, Nagpur issued approval IEC/Pharmac/2020/140 dated 2nd July 2020. Institutional Ethics Committee approval was obtained before initiating the study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. (2022). Accessed: May 13, 2022: https://covid19.who.int.
2. Williamson EJ, Walker AJ, Bhaskaran K, et al.: Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020, 584:430-6. 10.1038/s41551-020-2521-4
3. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016/S0140-6736(20)30183-5
4. Ruan Q, Yang K, Wang W, Jiang L, Song J: Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46:846-8. 10.1007/s00134-020-05991-x
5. Guthrie GJ, Charles KA, Roxburgh CS, Horgon PG, McMillan DC, Clarke SJ: The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2015, 88:218-30. 10.1016/j.critrevonc.2015.03.010
6. Imtiaz F, Shafique K, Mirza SS, Ayob Z, Vart P, Rao S: Neutrophil lymphocyte ratio as a measure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med. 2012, 5:2. 10.1186/1755-7682-5-2
7. Kim S, Eliot M, Koestler DC, Wu WC, Kelsey KT: Association of neutrophil-to-lymphocyte ratio with mortality and cardiovascular disease in the Jackson Heart Study and modification by the Duffy Antigen Variant. JAMA Cardiol. 2018, 3:455-62. 10.1001/jamacardio.2018.1042
8. Palogiannis P, Pois AG, Sotgia S, et al.: Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev. 2018, 27:170113. 10.1183/16000617.0113-2017
9. Kong W, He Y, Yao H, Zhang W, Wang X: Diagnostic value of neutrophil-lymphocyte ratio for predicting the severity of acute pancreatitis: a meta-analysis. Dis Markers. 2020, 2020:1-9. 10.1155/2020/9731854
10. Lian J, Jin C, Hao S, et al.: High neutrophil-to-lymphocyte ratio associated with progression to critical illness in older patients with COVID-19: a multicenter retrospective study. Aging. 2020, 12:15849-59.
11. Zhang J, Cao Y, Tan G, et al.: Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy. 2021, 76:533-50. 10.1111/all.14946
12. Fu J, Kong J, Wang W, et al.: The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: a retrospective study in Suzhou China. Thromb Res. 2020, 192:5-8. 10.1016/j.thromres.2020.05.006
13. Liao D, Zhou F, Luo L, et al.: Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020, 7:e671-8. 10.1016/S2552-3306(20)30217-9
14. Ma A, Cheng J, Yang J, Dong M, Liao X, Kang Y: Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate–severe ARDS in severe COVID-19 patients. Crit Care. 2020, 24:1-4. 10.1186/s13054-020-03007-0
15. Son KB, Lee TJ, Hwang SS: Disease severity classification and COVID-19 outcomes, Republic of Korea. Bull World Health Organ. 2021, 99:62-6. 10.2471/BLT.20.257758
16. Forget P, Khalifa C, Defour JP, Latinne D, Van Pet MC, De Kock M: What is the normal value of the neutrophil-to-lymphocyte ratio?. BMC Res Notes. 2017, 10:1-4. 10.1186/s13104-016-2355-5
17. Liu YP, Li GM, He J, et al.: Combined use of the neutrophil-to-lymphocyte ratio and CRP to predict 7-day disease severity in 84 hospitalized patients with COVID-19 pneumonia: a retrospective cohort study. Ann Transl Med. 2020, 8:1-11. 10.21037/atm-20-2572
18. Liu J, Liu Y, Xiang P, et al.: Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med. 2020, 18:1-12. 10.1186/s12977-020-02574-0
19. Yan X, Li F, Wang X, et al.: Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: a retrospective cross-sectional study. J Med Virol. 2020, 92:2573-81. 10.1002/jmv.26061
20. Zeng ZY, Feng SD, Chen GP, Wu JN: Predictive value of the neutrophil to lymphocyte ratio for disease deterioration and serious adverse outcomes in patients with COVID-19: a prospective cohort study. BMC Infect Dis. 2021, 21:1-6. 10.1186/s12879-021-02576-3
21. Chan AS, Rout A: Use of neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in COVID-19. J Clin Med Res. 2020, 12:448-53. 10.14740/jcmr2420
22. Ma X, Liu C, Mao Z, Xiao M, Wang L, Qi S, Zhou F: Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. Crit Care. 2020, 24:1-10. 10.1186/s13054-020-03574-8
23. Liu CC, Ko HJ, Liu WS, Hung CL, Hu KC, Yu LY, Shih SC: Neutrophil-to-lymphocyte ratio as a predictive marker of metabolic syndrome. Medicine. 2019, 98:e17537. 10.1097/MD.0000000000017537
24. Dettorre GM, Dolly S, Loizidou A, et al.: Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. J Immunoother Cancer. 2021, 9:e002277. 10.1136/jitc-2020-002277
25. Liu Y, Du X, Chen J, et al.: Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020, 81:e6-e12. 10.1016/j.jinf.2020.04.002
26. Seyit M, Avci E, Nar R, et al.: Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med. 2021, 40:110-4. 10.1016/j.ajem.2020.11.058
27. Nair PR, Maira V, Ray BR, Anand RK, Baidya DK, Subramaniam R: Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as predictors of the early requirement of mechanical ventilation in COVID-19 patients. Indian J Crit Care Med. 2020, 24:1143-4. 10.5005/jp-journals-10071-25663
28. Prescott HC, Girard TD: Recovery from severe COVID-19: leveraging the lessons of survival from sepsis. JAMA. 2020, 324:759-40. 10.1001/jama.2020.14103
29. Cao Y, Hiyoshi A, Montgomery S: COVID-19 case-fatality rate and demographic and socioeconomic influencers: worldwide spatial regression analysis based on country-level data. BMJ Open. 2020, 10:e045560. 10.1136/bmjopen-2020-045560
30. Xia X, Weng M, Zhan S, He J, Chen W: An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19. J Infect. 2020, 80:542-5. 10.1212/jian.1675-4254.2020.05.06
31. Khourraji M, Chapelle V, Evenspeel A, et al.: A biological profile for diagnosis and outcome of COVID-19 patients. Clin Chem Lab Med. 2020, 58:2141-50. 10.1515/cclm-2020-0626
32. Ni L, Ye F, Cheng ML, et al.: Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020, 52:971-977.e5. 10.1016/j.immuni.2020.04.023
33. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, Gao GF: T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV. Antivir Res. 2017, 157:82-92. 10.1016/j.antiviral.2016.11.006
34. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C: Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020, 11:1-13. 10.3389/fimmu.2020.01708
35. Remondo S, Ventura PS, Castellano MJ, et al.: Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest. 2021, 51:e13404. 10.1111/ect.13404
36. Ullah W, Basayal B, Tariq S, et al.: Lymphocyte-to-C-reactive protein ratio: a novel predictor of adverse outcomes in COVID-19. J Clin Med Res. 2020, 12:415-22. 10.14740/jcmr4227
37. SeyyedAliMoghazi S, Mirzapour P, Dadras O, et al.: Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021, 26:1-20. 10.1186/s40001-021-00524-8